Dupilumab (Dupixent®): Efficacy and treatment satisfaction in patients with atopic dermatitis

Abstract

Introduction Atopic dermatitis (AD) is the most common chronic inflammatory skin condition worldwide. In 2017, dupilumab was approved in the EU for use in moderate to severe forms of AD, providing a reliable long-term therapy and relief of disease symptoms. Alongside the reduction of the symptoms, it offered a long-lasting improvement in quality of life, reducing itch and sleep disturbances. As of 2020, there was no data from Austria regarding the long-term use of dupilumab for this indication. Aim of the study This study aimed to demonstrate the long-term clinical efficacy of dupilumab in moderate-to-severe forms of AD and to investigate its impact on long-term quality of life and patients’ satisfaction with the therapy. Methods This study consists of two parts - a retrospective and a prospective one. For the retrospective part, we conducted a retrospective analysis of the data from 142 cases from the Outpatient Unit for atopic dermatitis at the Department of Dermatology and Venereology, at LKH-Universitätsklinikum in Graz that has been collected between January 2017 and February 2024. Three time points for data collection were analysed: at baseline, after 3 months, and after one year of therapy. As for the prospective part, a specifically developed online questionnaire gathered feedback from 85 patients about the relief of the symptoms, side effects, the form of administration, and failed injections. Results After one year of therapy, the mean worst itch NRS reduction amounted to 4.9 points (p

Datum der Bewilligung	2024
Originalsprache	Englisch
Gradverleihende Hochschule	Medizinische Universität Graz
Betreuer/-in	Franz Legat (Betreuer*in) & Maria-Lisa Repelnig (Mitbetreuer*in)